{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:02:14Z","timestamp":1792785734272,"version":"4.5.0"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002338","name":"Changjiang Scholars and Innovative Research Team in Universities, Ministry of Education of China","doi-asserted-by":"publisher","award":["IRT_15R55"],"award-info":[{"award-number":["IRT_15R55"]}],"id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hundred-Talent Program of Shaanxi Province"},{"name":"International Science & Technology Cooperation Program of Shaanxi Province","award":["2019KWZ-001"],"award-info":[{"award-number":["2019KWZ-001"]}],"id":[{"id":"https:\/\/ror.org\/00bsdxt65","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2017JM8054)."],"award-info":[{"award-number":["2017JM8054)."]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ejmech.2019.111893","type":"journal-article","created":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T17:41:40Z","timestamp":1573926100000},"page":"111893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":231,"special_numbering":"C","title":["Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect"],"prefix":"10.1016","volume":"186","author":[{"given":"Zefeng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peinan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingcheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xirui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6235-7687","authenticated-orcid":false,"given":"Shaoping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8493-5812","authenticated-orcid":false,"given":"Yongmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0738-4943","authenticated-orcid":false,"given":"Xiaohui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.111893_bib1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ejmech.2014.11.059","article-title":"Recent advances in bioactive pyrazoles","volume":"97","author":"Kucukguzel","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib2","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1517\/14656566.2010.493558","article-title":"A\u00a0critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?","volume":"11","author":"Lapchak","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2019.111893_bib3","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1093\/clinchem\/24.12.2161","article-title":"The 4-hydroxybenzoate\/4-aminophenazone chromogenic system used in the enzymic determination of serum cholesterol","volume":"24","author":"Meiattini","year":"1978","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib4","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2019.111893_bib5","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMoa073255","article-title":"Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C, N","volume":"357","author":"McHutchison","year":"2007","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.ejmech.2019.111893_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1526-4610.2001.111006391.x","article-title":"Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine","volume":"41","author":"Freitag","year":"2001","journal-title":"Headache"},{"key":"10.1016\/j.ejmech.2019.111893_bib7","first-page":"39","article-title":"Sulphenazone in pediatric practice","volume":"34","author":"Pecenco","year":"1982","journal-title":"Case studies, Minerva Pediatr."},{"key":"10.1016\/j.ejmech.2019.111893_bib8","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1067\/mai.2003.163","article-title":"IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone","volume":"111","author":"Himly","year":"2003","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2019.111893_bib9","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1136\/bmj.1.5397.1553","article-title":"Trial of nifenazone (\"THYLIN\")","volume":"1","author":"Hart","year":"1964","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejmech.2019.111893_bib10","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.ccr.2007.02.010","article-title":"Coordination modes of 5-pyrazolones: a solid-state overview","volume":"251","author":"Casas","year":"2007","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.111893_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/tcr.201800199","article-title":"Catalytic asymmetric synthesis of spiropyrazolones and their application in medicinal chemistry","volume":"19","author":"Xie","year":"2019","journal-title":"Chem. Rec."},{"key":"10.1016\/j.ejmech.2019.111893_bib12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2174\/138527212799499921","article-title":"Chemistry of pyrazolinones and their applications","volume":"16","author":"Hamama","year":"2012","journal-title":"Curr. Org. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib13","doi-asserted-by":"crossref","first-page":"11515","DOI":"10.1039\/C8CC06196C","article-title":"Pyrazolone: a powerful synthon for asymmetric diverse derivatizations","volume":"54","author":"Liu","year":"2018","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2019.111893_bib14","doi-asserted-by":"crossref","first-page":"8856","DOI":"10.3390\/molecules20058856","article-title":"Silver nanoparticles as potential antibacterial agents","volume":"20","author":"Franci","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2019.111893_bib15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejmech.2005.01.013","article-title":"Synthesis, antibacterial and antifungal activity of some new thiazolylhydrazone derivatives containing 3-substituted cyclobutane ring","volume":"41","author":"Cukurovali","year":"2006","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.apsb.2016.06.004","article-title":"A\u00a0review of global initiatives to fight antibiotic resistance and recent antibiotics\u2019 discovery","volume":"6","author":"Chaudhary","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2019.111893_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.apsb.2016.05.010","article-title":"Self-enhanced targeted delivery of a cell wall- and membrane-active antibiotics, daptomycin, against staphylococcal pneumonia","volume":"6","author":"Jiang","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2019.111893_bib18","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.carres.2009.06.003","article-title":"A\u00a0facile synthesis, structure, and antimicrobial evaluation of novel 4-arylhydrazono-5-trifluoromethyl-2,4-dihydropyrazol-3-ones, their N- and N,O-bis-beta-D-glucosides","volume":"344","author":"Khalil","year":"2009","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2019.111893_bib19","first-page":"223","article-title":"Discovery of imrecoxib","volume":"21","author":"Guo","year":"2012","journal-title":"Chin. J. N. Drugs"},{"key":"10.1016\/j.ejmech.2019.111893_bib20","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1248\/cpb.55.1704","article-title":"Synthesis and bioassay of amino-pyrazolone, amino-isoxazolone and amino-pyrimidinone derivatives","volume":"55","author":"Padmavathi","year":"2007","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2019.111893_bib21","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1016\/j.ejmech.2011.07.035","article-title":"Design and synthesis of some new thiophene, thienopyrimidine and thienothiadiazine derivatives of antipyrine as potential antimicrobial agents","volume":"46","author":"Aly","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/jhet.806","article-title":"A\u00a0versatile synthesis, PM3-semiempirical, antibacterial, and antitumor evaluation of some bioactive pyrazoles","volume":"49","author":"Hamama","year":"2012","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib23","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1016\/j.bmcl.2013.03.123","article-title":"Detour of prenostodione synthesis towards pyrazolones for antibacterial activity","volume":"23","author":"Rasapalli","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib24","first-page":"741953","article-title":"Ultrasonication-induced synthesis and antimicrobial evaluation of some multifluorinated pyrazolone derivatives","author":"Gadhave","year":"2013","journal-title":"J.\u00a0Chem. Neuroanat."},{"key":"10.1016\/j.ejmech.2019.111893_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pharma.2013.11.005","article-title":"In\u00a0vitro microbiological evaluation of novel bis pyrazolones","volume":"72","author":"Narayana Rao","year":"2014","journal-title":"Ann. Pharm. Fr."},{"key":"10.1016\/j.ejmech.2019.111893_bib26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13065-017-0339-4","article-title":"Synthesis, characterization and in\u00a0vitro antimicrobial activity of novel fused pyrazolo[3,4-c]pyridazine, pyrazolo[3,4-d]pyrimidine, thieno[3,2-c]pyrazole and pyrazolo[3\u2019,4\u2019:4,5]thieno[2,3-d]pyrimidine derivatives","volume":"11","author":"Reheim","year":"2017","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.ejmech.2019.111893_bib27","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.4314\/tjpr.v17i11.18","article-title":"Synthesis, antimicrobial evaluation and docking studies of new pyrazolone derivatives","volume":"17","author":"Alkhaldi","year":"2018","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.ejmech.2019.111893_bib28","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1016\/j.bmc.2018.08.033","article-title":"A\u00a0reusable magnetic nickel nanoparticle based catalyst for the aqueous synthesis of diverse heterocycles and their evaluation as potential anti-bacterial agent","volume":"26","author":"Bhattacharjee","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.molcata.2015.11.004","article-title":"Ce\/SiO2 composite as an efficient catalyst for the multicomponent one-pot synthesis of substituted pyrazolones in aqueous media and their antimicrobial activities","volume":"411","author":"Akondi","year":"2016","journal-title":"J.\u00a0Mol. Catal. A Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.molliq.2017.12.156","article-title":"Pyrazole, pyrazolone and enaminonitrile pyrazole derivatives: synthesis, characterization and potential in corrosion inhibition and antimicrobial applications","volume":"252","author":"Sayed","year":"2018","journal-title":"J.\u00a0Mol. Liq."},{"key":"10.1016\/j.ejmech.2019.111893_bib31","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00044-013-0636-y","article-title":"Synthesis, evaluation and docking studies on steroidal pyrazolones as anticancer and antimicrobial agents","volume":"23","author":"Shamsuzzaman","year":"2014","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2019.111893_bib32","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3390\/molecules23092092","article-title":"Design, synthesis, and antimicrobial evaluation of novel pyrazoles and pyrazolyl 1,3,4-thiadiazine derivatives","volume":"23","author":"Radini","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2019.111893_bib33","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1016\/j.bmcl.2015.10.088","article-title":"PPL catalyzed four-component PASE synthesis of 5-monosubstituted barbiturates: structure and pharmacological properties","volume":"25","author":"Bihani","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib34","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1002\/slct.201800174","article-title":"2,4-Disubstituted phenylhydrazonopyrazolone and isoxazolone derivatives as antibacterial agents: synthesis, preliminary biological evaluation and docking studies","volume":"3","author":"Oraby","year":"2018","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.ejmech.2019.111893_bib35","first-page":"753","article-title":"Antibiofihn agents: a new perspective for antimicrobial strategy","volume":"55","author":"Li","year":"2017","journal-title":"J.\u00a0Microbiol."},{"key":"10.1016\/j.ejmech.2019.111893_bib36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1099\/mic.0.037143-0","article-title":"Metals, minerals and microbes: geomicrobiology and bioremediation","volume":"156","author":"Gadd","year":"2010","journal-title":"Microbiol. Sgm"},{"key":"10.1016\/j.ejmech.2019.111893_bib37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejmech.2019.04.032","article-title":"Perspectives of medicinally privileged chalcone based metal coordination compounds for biomedical applications","volume":"174","author":"Mahapatra","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib38","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/med.21301","article-title":"Flavonoid-metal ion complexes: a novel class of therapeutic agents","volume":"34","author":"Selvaraj","year":"2014","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2019.111893_bib39","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/S0277-5387(99)00230-2","article-title":"Group 12 metal complexes of tetradentate N 2 O 2 \u2013Schiff-base ligands incorporating pyrazole : synthesis, characterisation and reactivity toward S-donors, N-donors, copper and tin acceptors","volume":"18","author":"Marchetti","year":"1999","journal-title":"Polyhedron"},{"key":"10.1016\/j.ejmech.2019.111893_bib40","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/aoc.1782","article-title":"Mn(III) mixed-ligand complexes with bis-pyrazolones and ciprofloxacin drug: synthesis, characterization and antibacterial activities","volume":"25","author":"Modi","year":"2011","journal-title":"Appl. Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib41","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.poly.2011.11.004","article-title":"Syntheses, characterization and molecular structures of calcium(II) and copper(II) complexes bearing O-2-chelate ligands: DNA binding, DNA cleavage and anti-microbial study","volume":"31","author":"Jadeja","year":"2012","journal-title":"Polyhedron"},{"key":"10.1016\/j.ejmech.2019.111893_bib42","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.molstruc.2014.10.056","article-title":"Syntheses, crystal structure and biological evaluation of Schiff bases and copper complexes derived from 4-formylpyrazolone","volume":"1081","author":"Joseph","year":"2015","journal-title":"J.\u00a0Mol. Struct."},{"key":"10.1016\/j.ejmech.2019.111893_bib43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jorganchem.2017.11.012","article-title":"Synthesis, characterization and biological applications of substituted pyrazolone core based platinum(II) organometallic compounds","volume":"854","author":"Lunagariya","year":"2018","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib44","first-page":"S591","article-title":"Synthesis, characterization and biological studies on some metal complexes with Schiff base ligand containing pyrazolone moiety","volume":"20","author":"Nair","year":"2016","journal-title":"J.\u00a0Saudi Chem. Soc."},{"key":"10.1016\/j.ejmech.2019.111893_bib45","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(12)70211-5","article-title":"Global cancer transitions according to the Human Development Index (2008\u20132030): a population-based study","volume":"13","author":"Bray","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2019.111893_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bmc.2005.09.059","article-title":"Synthesis and biological activity of N,N-dialkylaminoalkyl-substituted bisindolyl and diphenyl pyrazolone derivatives","volume":"14","author":"Bra\u00f1a","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib47","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.yexcr.2005.11.012","article-title":"Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis","volume":"312","author":"Masabumi","year":"2006","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2019.111893_bib48","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/med.21517","article-title":"New strategies in achieving antiangiogenic effect: multiplex inhibitors suppressing compensatory activations of RTKs","volume":"38","author":"Shan","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2019.111893_bib49","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.bmcl.2006.01.063","article-title":"Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis","volume":"16","author":"Tripathy","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.111893_bib50","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1016\/j.bmcl.2011.10.055","article-title":"Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group","volume":"21","author":"Tripathy","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bioorg.2017.04.001","article-title":"Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met\/VEGFR-2 receptor tyrosine kinase inhibitors","volume":"72","author":"Gu","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib52","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1021\/jm201330u","article-title":"Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives","volume":"55","author":"Norman","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib53","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1021\/jm201331s","article-title":"Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series","volume":"55","author":"Longbin","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib54","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bioorg.2014.07.011","article-title":"Design, synthesis and pharmacological evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents","volume":"57","author":"Zhou","year":"2014","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib55","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1021\/jm4018064","article-title":"Development of pyrazolone and isoxazol-5-one cambinol analogues as Sirtuin inhibitors","volume":"57","author":"Mahajan","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib56","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1039\/C8QO00422F","article-title":"Application of organocatalysis in bioorganometallic chemistry: asymmetric synthesis of multifunctionalized spirocyclic pyrazolone-ferrocene hybrids as novel RalA inhibitors","volume":"5","author":"Zhang","year":"2018","journal-title":"Org. Chem. Front."},{"key":"10.1016\/j.ejmech.2019.111893_bib57","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1016\/j.bmcl.2011.06.025","article-title":"Antiproliferative activity and QSAR studies of a series of new 4-aminomethylidene derivatives of some pyrazol-5-ones","volume":"21","author":"Markovic","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib58","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.3390\/ijms15057539","article-title":"Synthesis, characterization and anti-breast cancer activity of new 4-aminoantipyrine-based heterocycles","volume":"15","author":"Ghorab","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2019.111893_bib59","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s00044-014-1201-z","article-title":"Synthesis of novel 5-methyl pyrazol-3-one derivatives and their in\u00a0vitro cytotoxic evaluation","volume":"24","author":"Dube","year":"2015","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2019.111893_bib60","first-page":"151","article-title":"Synthesis and antitumor evaluation of thiophene based azo dyes incorporating pyrazolone moiety","volume":"20","author":"Gouda","year":"2016","journal-title":"J.\u00a0Saudi. Chem. Soc."},{"key":"10.1016\/j.ejmech.2019.111893_bib61","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.poly.2013.08.051","article-title":"A\u00a0new pyrazolone based ternary Cu(II) complex: synthesis, characterization, crystal structure, DNA binding, protein binding and anti-cancer activity towards A549 human lung carcinoma cells with a minimum cytotoxicity to non-cancerous cells","volume":"65","author":"Vyas","year":"2013","journal-title":"Polyhedron"},{"key":"10.1016\/j.ejmech.2019.111893_bib62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejmech.2014.02.039","article-title":"Novel mixed ligand di-n-butyltin(IV) complexes derived from acylpyrazolones and fluorinated benzoic acids: synthesis, characterization, cytotoxicity and the induction of apoptosis in Hela cancer cells","volume":"76","author":"Zhao","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib63","doi-asserted-by":"crossref","first-page":"e4104","DOI":"10.1002\/aoc.4104","article-title":"New Ni(II), Pd(II) and Pt(II) complexes coordinated to azo pyrazolone ligand with a potent anti-tumor activity: synthesis, characterization, DFT and DNA cleavage studies","volume":"32","author":"Bakr","year":"2018","journal-title":"Appl. Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib64","doi-asserted-by":"crossref","first-page":"e4668","DOI":"10.1002\/aoc.4668","article-title":"Synthesis, crystal structure, DNA\/bovine serum albumin binding and antitumor activity of two transition metal complexes with 4-acylpyrazolone derivative","volume":"33","author":"Zhang","year":"2019","journal-title":"Appl. Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib65","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejmech.2019.04.028","article-title":"Comprehensive review on the interaction between natural compounds and brain receptors: benefits and toxicity","volume":"174","author":"Silva","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib66","first-page":"1","article-title":"Excavating anticonvulsant compounds from prescriptions of Traditional Chinese Medicine in the treatment of epilepsy","author":"Zhao","year":"2018","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.ejmech.2019.111893_bib67","first-page":"1785","article-title":"Synthesis of new pyrazolone-based heterocycles as inhibitors of monoamine oxidase enzymes","volume":"15","author":"Eldebss","year":"2018","journal-title":"J.\u00a0Iran. Chem. Soc."},{"key":"10.1016\/j.ejmech.2019.111893_bib68","doi-asserted-by":"crossref","first-page":"94786","DOI":"10.1039\/C5RA17391D","article-title":"Design, synthesis, anticonvulsant and analgesic studies of new pyrazole analogues: a Knoevenagel reaction approach","volume":"5","author":"Viveka","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2019.111893_bib69","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1016\/j.ejmech.2009.01.032","article-title":"Synthesis of novel pyrazole derivatives and evaluation of their antidepressant and anticonvulsant activities","volume":"44","author":"Abdel-Aziz","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib70","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3329\/bjp.v11i2.25859","article-title":"Synthesis and anti-depressant evaluation of novel pyrazolone derivatives","volume":"11","author":"Merugumolu","year":"2016","journal-title":"Bangladesh J. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.111893_bib71","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1146\/annurev.neuro.27.070203.144244","article-title":"Unraveling the mechanisms involved in motor neuron degeneration in ALS","volume":"27","author":"Bruijn","year":"2004","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2019.111893_bib72","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1212\/01.wnl.0000258551.96893.6f","article-title":"Ethnic variation in the incidence of ALS - a systematic review","volume":"68","author":"Cronin","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2019.111893_bib73","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/17482968.2010.522586","article-title":"Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis","volume":"12","author":"Benmohamed","year":"2011","journal-title":"Amyotroph Lateral Scler."},{"key":"10.1016\/j.ejmech.2019.111893_bib74","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1021\/jm2014277","article-title":"ADME-Guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of Amyotrophic Lateral Sclerosis","volume":"55","author":"Chen","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bioorg.2018.11.016","article-title":"Synthesis and biological evaluation of new pyrazolone Schiff bases as monoamine oxidase and cholinesterase inhibitors","volume":"84","author":"Tok","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib76","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0163-7258(95)02043-8","article-title":"GABAA receptor pharmacology","volume":"69","author":"Johnston","year":"1996","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2019.111893_bib77","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ejmech.2019.03.043","article-title":"GABA allosteric modulators: an overview of recent developments in non-benzodiazepine modulators","volume":"171","author":"Solomon","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib78","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.bmcl.2010.12.107","article-title":"Exploring subtype selectivity and metabolic stability of a novel series of ligands for the benzodiazepine binding site of the GABA(A) receptor","volume":"21","author":"Hintermann","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib79","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1517\/13543776.15.10.1315","article-title":"GSK-3 inhibitors and their potential in the treatment of Alzheimer\u2019s disease","volume":"15","author":"Kypta","year":"2005","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2019.111893_bib80","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.phrs.2015.03.010","article-title":"Glycogen synthase kinase-3 beta (GSK-3 beta) signaling: implications for Parkinson\u2019s disease","volume":"97","author":"Golpich","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2019.111893_bib81","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2174\/0929867043455738","article-title":"GSK-3 inhibitors: discoveries and developments","volume":"11","author":"Alonso","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib82","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/cmdc.201100231","article-title":"Structure-guided design of a highly selective glycogen synthase kinase-3 beta inhibitor: a superior neuroprotective pyrazolone showing antimania effects","volume":"6","author":"Chen","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.111893_bib83","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3233\/JAD-2008-15204","article-title":"GSK-3 Inhibitors: a ray of hope for the treatment of Alzheimer\u2019s disease?","volume":"15","author":"Martinez","year":"2008","journal-title":"J.\u00a0Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejmech.2019.111893_bib84","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1021\/jm040895g","article-title":"SAR and 3D-QSAR studies on thiadiazolidinone derivatives:\u2009 exploration of structural requirements for glycogen synthase kinase 3 inhibitors","volume":"48","author":"Martinez","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib85","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0223-5234(99)00122-1","article-title":"3-Pyrazolone analogues of the 3-isoxazolol metabotropic excitatory amino acid receptor agonist homo-AMPA. Synthesis and pharmacological testing","volume":"34","author":"Zimmermann","year":"1999","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib86","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1366-0071(97)80033-2","article-title":"The early history of non-opioid analgesics","volume":"1","author":"Brune","year":"1997","journal-title":"Acute Pain"},{"key":"10.1016\/j.ejmech.2019.111893_bib87","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1016\/j.bmcl.2012.07.088","article-title":"Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3\/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones","volume":"22","author":"Ochiai","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib88","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejmech.2019.03.036","article-title":"Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents","volume":"171","author":"Ahmed","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib89","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ejmech.2016.08.013","article-title":"Novel N-substituted indole Schiff bases as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase enzymes: synthesis, biological activities in\u00a0vitro and docking study","volume":"123","author":"Lamie","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib90","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0223-5234(02)01373-9","article-title":"Investigations of new lead structures for the design of novel cyclooxygenase-2 inhibitors","volume":"37","author":"Park","year":"2002","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib91","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.apsb.2016.08.006","article-title":"Synthesis, characterization and pharmacological evaluation of pyrazolyl urea derivatives as potential anti-inflammatory agents","volume":"7","author":"Somakala","year":"2017","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2019.111893_bib92","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jsps.2011.05.006","article-title":"Microwave assisted synthesis of novel pyrazolone derivatives attached to a pyrimidine moiety and evaluation of their anti-inflammatory, analgesic and antipyretic activities","volume":"19","author":"Antre","year":"2011","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.ejmech.2019.111893_bib93","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.bmc.2014.02.042","article-title":"Synthesis and biological evaluation of new pyrazolone-pyridazine conjugates as anti-inflammatory and analgesic agents","volume":"22","author":"Khalil","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib94","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1016\/j.bmcl.2014.04.067","article-title":"Conventional and microwave assisted synthesis of pyrazolone Mannich bases possessing anti-inflammatory, analgesic, ulcerogenic effect and antimicrobial properties","volume":"24","author":"Sivakumar","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.111893_bib95","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1007\/s00044-014-0935-y","article-title":"Synthesis and biological activity of some new pyridines, pyrans, and indazoles containing pyrazolone moiety","volume":"23","author":"Abbady","year":"2014","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2019.111893_bib96","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/cbdd.12324","article-title":"Synthesis and biologic evaluation of substituted 5-methyl-2-phenyl-1H-pyrazol-3(2H)-one derivatives as selective COX-2 Inhibitors: molecular docking study","volume":"84","author":"Dube","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2019.111893_bib97","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/cbdd.12712","article-title":"Synthesis of novel substituted thiourea and benzimidazole derivatives containing a pyrazolone ring as anti-inflammatory agents","volume":"87","author":"Moneer","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2019.111893_bib98","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bmcl.2018.01.043","article-title":"Design, synthesis, anti-inflammatory activity and molecular docking of potential novel antipyrine and pyrazolone analogs as cyclooxygenase enzyme (COX) inhibitors","volume":"28","author":"El Sayed","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib99","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bioorg.2018.03.011","article-title":"Design, synthesis, analgesic, anti-inflammatory activity of novel pyrazolones possessing aminosulfonyl pharmacophore as inhibitors of COX-2\/5-LOX enzymes: histopathological and docking studies","volume":"78","author":"Abdelgawad","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF02978252","article-title":"Synthesis and evaluation of the analgesic and antiinflammatory activities of O-substituted salicylamides","volume":"24","author":"Fahmy","year":"2001","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.ejmech.2019.111893_bib101","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.bmcl.2005.03.007","article-title":"The development of monocyclic pyrazolone based cytokine synthesis inhibitors","volume":"15","author":"Golebiowski","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"Suppl 7","key":"10.1016\/j.ejmech.2019.111893_bib102","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/09637480903012355","article-title":"Kiwifruit-based polyphenols and related antioxidants for functional foods: kiwifruit extract-enhanced gluten-free bread","volume":"60","author":"Sun-Waterhouse","year":"2009","journal-title":"Int. J. Food Sci. Nutr."},{"key":"10.1016\/j.ejmech.2019.111893_bib103","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/157489006775244191","article-title":"Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases","volume":"1","author":"Higashi","year":"2006","journal-title":"Recent Pat. Cardiovasc. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.111893_bib104","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10870-011-0209-1","article-title":"Synthesis, molecular structure and antioxidant activity of (E)-4- Benzylideneamino -1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one, a Schiff Base ligand of 4-Aminoantipyrine","volume":"42","author":"Alam","year":"2012","journal-title":"J.\u00a0Chem. Crystallogr."},{"key":"10.1016\/j.ejmech.2019.111893_bib105","first-page":"802","article-title":"Synthesis of 4-amino-1,5-dimethyl-2-phenylpyrazolone derivatives and their antioxidant activity","volume":"37","author":"Khan","year":"2015","journal-title":"J.\u00a0Chem. Soc. Pakistan"},{"key":"10.1016\/j.ejmech.2019.111893_bib106","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jhet.2588","article-title":"Synthesis and antioxidant activity of some new thiazolyl-pyrazolone derivatives","volume":"54","author":"Gaffer","year":"2017","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib107","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ejmech.2019.01.002","article-title":"Synthesis and evaluation of alpha-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis","volume":"164","author":"Makane","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2019.01.073","article-title":"Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors","volume":"167","author":"Patel","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib109","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ardp.201600019","article-title":"Design, synthesis, and characterization of some hybridized pyrazolone pharmacophore analogs against Mycobacterium tuberculosis","volume":"349","author":"Krishnasamy","year":"2016","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2019.111893_bib110","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1016\/j.ejmech.2011.07.029","article-title":"A\u00a0facile four-component sequential protocol in the expedient synthesis of novel 2-aryl-5-methyl-2,3-dihydro-1H-3-pyrazolones in water and their antitubercular evaluation","volume":"46","author":"Gunasekaran","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib111","doi-asserted-by":"crossref","first-page":"8587","DOI":"10.1016\/j.bmc.2008.08.016","article-title":"Synthesis, biological evaluation and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis","volume":"16","author":"Castagnolo","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib112","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1016\/j.bmc.2009.05.058","article-title":"Synthesis, biological evaluation, and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: Part 2. Synthesis of rigid pyrazolones","volume":"17","author":"Castagnolo","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib113","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4103\/0250-474X.119832","article-title":"Synthesis, SAR study and evaluation of Mannich and Schiff bases of pyrazol-5(4H)-one moiety containing 3-(Hydrazinyl)-2-phenylquinazolin-4(3H)-one","volume":"75","author":"Sivakumar","year":"2013","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2019.111893_bib114","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1016\/j.bmcl.2011.10.057","article-title":"Molecular properties prediction and synthesis of novel 1,3,4-oxadiazole analogues as potent antimicrobial and antitubercular agents","volume":"21","author":"Ahsan","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib115","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.bmcl.2011.12.014","article-title":"Discovery of novel antitubercular 1,5-dimethyl-2-phenyl-4-([5-(arylamino)-1,3,4-oxadiazol-2-yl]methylamino)-1,2-dih ydro-3H-pyrazol-3-one analogues","volume":"22","author":"Ahsan","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib116","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejmech.2019.04.009","article-title":"Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives","volume":"173","author":"Zhao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib117","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1016\/j.bmcl.2006.03.043","article-title":"A\u00a0pyrimidine-pyrazolone nucleoside chimera with potent in\u00a0vitro anti-orthopoxvirus activity","volume":"16","author":"Fan","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib118","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1021\/jm070688r","article-title":"New series of antiprion compounds: pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation","volume":"50","author":"Kimata","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib119","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/1570180812666150630182740","article-title":"Design and synthesis of novel spiro-piperidinyl pyrazolone derivatives and their potential antiviral activity","volume":"13","author":"Srinivasan","year":"2016","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.ejmech.2019.111893_bib120","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1016\/j.bmc.2016.05.013","article-title":"Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors","volume":"24","author":"Kumar","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib121","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrd.2016.188","article-title":"Nonalcoholic steatohepatitis (NASH) drugs market","volume":"15","author":"Cassidy","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.111893_bib122","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2019.111893_bib123","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1021\/jm3002718","article-title":"Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists","volume":"55","author":"Huang","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib124","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2019.111893_bib125","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tips.2009.08.001","article-title":"Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders","volume":"30","author":"Fiorucci","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2019.111893_bib126","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tcb.2015.10.013","article-title":"AMPK: an energy-sensing pathway with multiple inputs and outputs","volume":"26","author":"Hardie","year":"2016","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2019.111893_bib127","doi-asserted-by":"crossref","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.111893_bib128","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/aps.2017.186","article-title":"Novel substituted pyrazolone derivatives as AMP-activated protein kinase activators to inhibit lipid synthesis and reduce lipid accumulation in ob\/ob mice","volume":"39","author":"Zhang","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2019.111893_bib129","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bioorg.2014.02.002","article-title":"Development of novel pyrazolone derivatives as inhibitors of aldose reductase: an eco-friendly one-pot synthesis, experimental screening and in silico analysis","volume":"53","author":"Kadam","year":"2014","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib130","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1021\/jm960444z","article-title":"New potent antihyperglycemic agents in db\/db mice: synthesis and structure-activity relationship studies of (4-substituted benzyl)(trifluoromethyl)pyrazoles and -pyrazolones","volume":"39","author":"Kees","year":"1996","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib131","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/jhet.3433","article-title":"Synthesis of some new pyrazolone-based heterocycles containing sulphone moiety acting as alpha-glucosidase and alpha-amylase inhibitors","volume":"56","author":"Eldebss","year":"2019","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib132","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1007\/s00044-013-0846-3","article-title":"Type II diabetes-related enzyme inhibition and molecular modeling study of a novel series of pyrazolone derivatives","volume":"23","author":"Shetty","year":"2014","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2019.111893_bib133","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.bmc.2004.01.038","article-title":"Structure-activity studies for a novel series of tricyclic dihydropyridopyrazolones and dihydropyridoisoxazolones as K(ATP) channel openers","volume":"12","author":"Drizin","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib134","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1016\/j.bmcl.2014.07.063","article-title":"Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors","volume":"24","author":"Amata","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1472-8206.2003.00167.x","article-title":"Treatment perspectives for human African trypanosomiasis","volume":"17","author":"Bouteille","year":"2003","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.111893_bib136","doi-asserted-by":"crossref","first-page":"8745","DOI":"10.1021\/jm301059b","article-title":"Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1","volume":"55","author":"Orrling","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib137","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/j.tetlet.2015.04.061","article-title":"Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1)","volume":"56","author":"Amata","year":"2015","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2019.111893_bib138","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/cbdd.12812","article-title":"Synthesis, biological evaluation, and molecular docking studies of new pyrazol-3-one derivatives with aromatase inhibition activities","volume":"88","author":"Yi","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2019.111893_bib139","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bmcl.2011.11.069","article-title":"Synthesis and biological evaluation of substituted pyrazoles as blockers of divalent metal transporter 1 (DMT1)","volume":"22","author":"Cadieux","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib140","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bmcl.2009.10.108","article-title":"Pyrazolone based TGFbetaR1 kinase inhibitors","volume":"20","author":"Guckian","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib141","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1021\/acs.orglett.8b01316","article-title":"Asymmetric construction of a multi-pharmacophore-containing dispirotriheterocyclic scaffold and identification of a human carboxylesterase 1 inhibitor","volume":"20","author":"Bao","year":"2018","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2019.111893_bib142","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1517\/17460441.2012.712513","article-title":"The application of bioisosteres in drug design for novel drug discovery: focusing on acid protease inhibitors","volume":"7","author":"Hamada","year":"2012","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.111893_bib143","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1021\/jm1013693","article-title":"Synopsis of some recent tactical application of bioisosteres in drug design","volume":"54","author":"Meanwell","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib144","doi-asserted-by":"crossref","first-page":"10792","DOI":"10.1002\/anie.201814681","article-title":"Automated de novo drug design: are we nearly there yet?","volume":"58","author":"Schneider","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2019.111893_bib145","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/j.bmcl.2018.06.046","article-title":"Recent applications of machine learning in medicinal chemistry","volume":"28","author":"Panteleev","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111893_bib146","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900045","article-title":"Quinolone derivatives: potential anti-HIV agent-development and application","volume":"352","author":"Wang","year":"2019","journal-title":"Arch. Der Pharm."},{"key":"10.1016\/j.ejmech.2019.111893_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103021","article-title":"Medicinal chemistry of indole derivatives: current to future therapeutic prospectives","volume":"89","author":"Kumari","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib148","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2174\/1386207317666140122101631","article-title":"\"Old friends in new guise\": exploiting privileged structures for scaffold re-evolution\/refining","volume":"17","author":"Song","year":"2014","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"10.1016\/j.ejmech.2019.111893_bib149","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.2174\/13816128113199990505","article-title":"Heterocycle-thioacetic acid motif: a privileged molecular scaffold with potent, broad-ranging pharmacological activities","volume":"19","author":"Song","year":"2013","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2019.111893_bib150","first-page":"1528","article-title":"Privileged scaffolds or promiscuous binders: a glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry","volume":"19","author":"Song","year":"2013","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2019.111893_bib151","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4155\/fmc-2018-0489","article-title":"Designing influenza polymerase acidic endonuclease inhibitors via \u2019privileged scaffold\u2019 re-evolution\/refining strategy","volume":"11","author":"Ju","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib152","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ejmech.2017.07.047","article-title":"Photoactivation provides a mechanistic explanation for pan-assay interference behaviour of 2-aminopyrroles in lipoxygenase inhibition","volume":"139","author":"Guo","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib153","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acs.jmedchem.6b01134","article-title":"Targeting type 2 diabetes with C-glucosyl dihydrochalcones as selective sodium glucose co-transporter 2 (SGLT2) inhibitors: synthesis and biological evaluation","volume":"60","author":"Jesus","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111893_bib154","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cej.2018.03.129","article-title":"Degradation behaviors and genetic toxicity variations of pyrazolone pharmaceuticals during chlorine dioxide disinfection process","volume":"345","author":"Jia","year":"2018","journal-title":"Chem. Eng. J."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419310451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419310451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:03:17Z","timestamp":1759327397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419310451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":154,"alternative-id":["S0223523419310451"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111893","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111893"}}